The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines after a safety concern was found to be unrelated ...
Novavax (NASDAQ:NVAX) shares climbed 12% premarket on Monday after the U.S. FDA lifted clinical hold on the investigational new drug application for the pharma firm’s COVID-19-Influenza ...
Novavax can move forward with a trial for its combined Covid-19 and influenza vaccine after regulators lifted a clinical hold ... plans to file for FDA approval of its own combo vaccine by ...
The lifted hold applies to Novavax’s flu ... combo vaccine. A trial participant who’d received the shot in Jan. 2023 later developed motor neuropathy, or muscle weakness, leading the FDA ...
(Reuters) -The U.S. Food and Drug Administration has lifted its clinical hold on ... combination shot and flu vaccine to ...
(Reuters) -The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID ... flu vaccines after a safety concern was found unrelated to the ...